AstraZeneca has acquired a £1.5 billion stake in United States drug developer Summit Therapeutics to accelerate research into an experimental cancer treatment.
The FTSE 100 pharmaceutical giant took a 12 per cent holding in Summit as part of a joint venture aimed at speeding up the development of ivonescimab, an experimental drug designed to attack cancer cells and stop them growing by targeting specific proteins.
The two firms will collaborate on the new medicine while investigating how ivonescimab can be combined with existing AstraZeneca treatments, specifically its sonesitatug vedotin drug, also known as Sone-Ve.
Clinical trials testing the combination therapy on patients with gastrointestinal cancer, a category of disease affecting digestive organs such as the stomach, liver, and colon, are scheduled to begin imminently.
Under the terms of the research agreement, both companies will contribute their respective medicines to the planned combination trials and share ongoing trial costs. Each group will retain development and commercial rights to its own medicine.
American expansion plan
The transaction follows a pledge made last year by AstraZeneca chief executive Pascal Soriot to invest $50 billion, equivalent to £38 billion, in the United States by 2030. AstraZeneca, which has expanded aggressively in North America, expects half of its global revenues to come from the country by the end of the decade.
AstraZeneca is one of the world's largest pharmaceutical companies, headquartered in Cambridge and listed on the London Stock Exchange, where it forms a major component of the blue-chip FTSE 100 index. The company specializes in oncology, cardiovascular, renal, and respiratory medicines.
Summit Therapeutics is a biopharmaceutical company focused on discovering and developing targeted therapies for serious medical conditions. Its primary focus is on novel oncology candidates that interfere with key molecular pathways required for tumor growth and cell survival.
Market reaction and analyst view
Following the announcement, Summit Therapeutics shares rose 5.5 per cent during trading in New York. AstraZeneca shares closed down 0.5 per cent in London after reaching a two-month high earlier in the day.
Minority stake acquisitions are frequently used in the pharmaceutical industry to establish strategic alliances with emerging biotechnology firms without committing to a full takeover.
Russ Mould, investment director at retail investment platform AJ Bell, said taking equity stakes in partner companies allows major drugmakers to gain direct access to promising drug pipelines.
Mould said: "Taking a stake in a partner is common in the pharma and biotech space, with the larger party effectively getting a seat at the table and being in prime position for a potential buyout down the line."
"It is a lower-risk way of dipping the toe in the water. If the collaboration doesn’t yield the required results, the larger party might just move on from the initial investment and not have wasted money from buying a company outright," Mould added.
Angeline Ong, an analyst at financial brokerage IG, described the investment as a "statement of intent" by AstraZeneca as it steps up its research presence and capital commitment in the US healthcare market.
Combining cancer therapies
AstraZeneca executive vice president Susan Galbraith emphasized the strategic potential of pairing Summit's candidate with AstraZeneca's antibody drug conjugates portfolio. Antibody drug conjugates are targeted cancer therapies designed to deliver potent therapeutic payloads directly to tumor cells while minimizing damage to healthy tissue.
Galbraith said: "This opportunity to combine ivonescimab with AstraZeneca’s antibody drug conjugates portfolio could enable new regimens that raise the bar for patients with cancer."
Dr Maky Zanganeh, president and co-chief executive of Summit Therapeutics, said: "The developments announced today with AstraZeneca open an exciting new chapter in the advancement of ivonescimab."
The two pharmaceutical companies will now move forward with trial preparations and patient monitoring as the gastrointestinal cancer combination studies prepare to launch.
